10-Q Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 Q2 2014

Filing Information

Form Type	10-Q
Accession Number	`0001144204-14-050058`
Period End Date	20140630
Filing Date	20140814
Fiscal Year	2014
Fiscal Period	Q2
XBRL Instance	bpth-20140630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 63 Income Statement 64 Cash Flow Statement 71

Balance Sheet 63 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash	`Cash`	$534.05K	USD	Point-in-time
Cash	`Cash`	-	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$15.72M	USD	Point-in-time
Cash	`Cash`	$1.93M	USD	Point-in-time
Cash	`Cash`	$3.55M	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid drug product for testing	`OtherInventory`	$141.34K	USD	Point-in-time
Prepaid drug product for testing	`OtherInventory`	$51.36K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$171.56K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$64.12K	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$16.03M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$3.67M	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	89.24M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	489,501.00	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	84.24M	shares	Point-in-time
Technology licenses - related party	`FiniteLivedLicenseAgreementsGross`	$2.50M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	89.24M	shares	Point-in-time
Technology licenses - related party	`FiniteLivedLicenseAgreementsGross`	$2.50M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	84.24M	shares	Point-in-time
Less Accumulated Amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$1.09M	USD	Point-in-time
Less Accumulated Amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$1.17M	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$1.33M	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$1.41M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$5.08M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$17.37M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$78.92K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$76.11K	USD	Point-in-time
Accounts payable - related party	`AccountsPayableRelatedPartiesCurrent`	-	USD	Point-in-time
Accounts payable - related party	`AccountsPayableRelatedPartiesCurrent`	$3.21K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$149.34K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$66.74K	USD	Point-in-time
Accrued expense - related party	`AccruedLiabilitiesRelatedPartiesCurrent`	$52.05K	USD	Point-in-time
Accrued expense - related party	`AccruedLiabilitiesRelatedPartiesCurrent`	$52.05K	USD	Point-in-time
Accrued license payments - related party	`DueToRelatedPartiesCurrent`	$50.00K	USD	Point-in-time
Accrued license payments - related party	`DueToRelatedPartiesCurrent`	$100.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$294.90K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$333.52K	USD	Point-in-time
Long term debt	`LongTermDebtNoncurrent`	-	USD	Point-in-time
Long term debt	`LongTermDebtNoncurrent`	-	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$333.52K	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$294.90K	USD	Point-in-time
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common Stock, $.001 par value, 200,000,000 shares authorized 89,237,872 and 84,237,872 shares issued and outstanding as of 6/30/14 and 12/31/13, respectively	`CommonStockValue`	$89.24K	USD	Point-in-time
Common Stock, $.001 par value, 200,000,000 shares authorized 89,237,872 and 84,237,872 shares issued and outstanding as of 6/30/14 and 12/31/13, respectively	`CommonStockValue`	$84.24K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$20.10M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$34.11M	USD	Point-in-time
Accumulated deficit during development stage	`DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage`	$15.40M	USD	Point-in-time
Accumulated deficit during development stage	`DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage`	$17.17M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$4.78M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$17.03M	USD	Point-in-time
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$5.08M	USD	Point-in-time
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$17.37M	USD	Point-in-time

Income Statement 64 line items

Line Item	Tag	Value	Unit	Period
Revenue	`Revenues`	-	USD	1 Quarter
Revenue	`Revenues`	-	USD	29 Qtrs
Revenue	`Revenues`	-	USD	1 Quarter
Revenue	`Revenues`	-	USD	2 Qtrs
Revenue	`Revenues`	-	USD	2 Qtrs
Technology impairment charge	`OtherAssetImpairmentCharges`	$345.00K	USD	Point-in-time
Technology impairment charge	`OtherAssetImpairmentCharges`	-	USD	2 Qtrs
Technology impairment charge	`OtherAssetImpairmentCharges`	-	USD	2 Qtrs
Technology impairment charge	`OtherAssetImpairmentCharges`	$690.00K	USD	29 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$557.13K	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$517.04K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$6.47M	USD	29 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$156.04K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$624.68K	USD	2 Qtrs
General & administrative	`GeneralAndAdministrativeExpense`	$1.14M	USD	2 Qtrs
General & administrative	`GeneralAndAdministrativeExpense`	$480.35K	USD	2 Qtrs
General & administrative	`GeneralAndAdministrativeExpense`	$240.54K	USD	1 Quarter
General & administrative	`GeneralAndAdministrativeExpense`	$9.83M	USD	29 Qtrs
General & administrative	`GeneralAndAdministrativeExpense`	$754.55K	USD	1 Quarter
Total operating expense	`OperatingExpenses`	$1.08M	USD	2 Qtrs
Total operating expense	`OperatingExpenses`	$1.79M	USD	2 Qtrs
Total operating expense	`OperatingExpenses`	$17.50M	USD	29 Qtrs
Total operating expense	`OperatingExpenses`	$428.65K	USD	1 Quarter
Total operating expense	`OperatingExpenses`	$1.27M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-1.08M	USD	2 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-1.27M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-17.50M	USD	29 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-1.79M	USD	2 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-428.65K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$11.64K	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$6.07K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$92.77K	USD	29 Qtrs
Interest income	`InvestmentIncomeInterest`	$1.53K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.66K	USD	2 Qtrs
Other income	`OtherNonoperatingIncome`	-	USD	1 Quarter
Other income	`OtherNonoperatingIncome`	-	USD	2 Qtrs
Other income	`OtherNonoperatingIncome`	-	USD	1 Quarter
Other income	`OtherNonoperatingIncome`	$244.48K	USD	29 Qtrs
Other income	`OtherNonoperatingIncome`	-	USD	2 Qtrs
Other expense	`OtherNonoperatingExpense`	$281.00	USD	2 Qtrs
Other expense	`OtherNonoperatingExpense`	$5.26K	USD	29 Qtrs
Other expense	`OtherNonoperatingExpense`	$42.00	USD	1 Quarter
Other expense	`OtherNonoperatingExpense`	$129.00	USD	1 Quarter
Other expense	`OtherNonoperatingExpense`	$345.00	USD	2 Qtrs
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$1.31K	USD	2 Qtrs
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$1.40K	USD	1 Quarter
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$11.36K	USD	2 Qtrs
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$6.02K	USD	1 Quarter
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$331.98K	USD	29 Qtrs
Net Loss	`NetIncomeLoss`	$-1.08M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-1.77M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-17.17M	USD	29 Qtrs
Net Loss	`NetIncomeLoss`	$-1.27M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-427.24K	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	2 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.33	USD	29 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	2 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	64.41M	shares	2 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89.24M	shares	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89.24M	shares	2 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	52.59M	shares	29 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	66.61M	shares	1 Quarter

Cash Flow Statement 71 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-1.08M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-1.77M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-17.17M	USD	29 Qtrs
Net loss	`NetIncomeLoss`	$-1.27M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-427.24K	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$80.31K	USD	2 Qtrs
Amortization	`AdjustmentForAmortization`	$1.22M	USD	29 Qtrs
Amortization	`AdjustmentForAmortization`	$80.31K	USD	2 Qtrs
Technology impairment	`OtherAssetImpairmentCharges`	$345.00K	USD	Point-in-time
Technology impairment	`OtherAssetImpairmentCharges`	-	USD	2 Qtrs
Technology impairment	`OtherAssetImpairmentCharges`	-	USD	2 Qtrs
Technology impairment	`OtherAssetImpairmentCharges`	$690.00K	USD	29 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	2 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	2 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$318.50K	USD	29 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$795.00K	USD	1 Quarter
Stock options and warrants	`ShareBasedCompensation`	$3.93M	USD	29 Qtrs
Stock options and warrants	`ShareBasedCompensation`	$29.56K	USD	2 Qtrs
Stock options and warrants	`ShareBasedCompensation`	$209.07K	USD	2 Qtrs
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$84.18K	USD	2 Qtrs
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$89.98K	USD	2 Qtrs
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$141.34K	USD	29 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$3.84K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$107.45K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$171.56K	USD	29 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-61.39K	USD	2 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$333.52K	USD	29 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$38.62K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-1.12M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-1.64M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-11.00M	USD	29 Qtrs
Purchase of exclusive license - related party	`PaymentsToAcquireIntangibleAssets`	$884.71K	USD	29 Qtrs
Purchase of exclusive license - related party	`PaymentsToAcquireIntangibleAssets`	-	USD	2 Qtrs
Purchase of exclusive license - related party	`PaymentsToAcquireIntangibleAssets`	-	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-884.71K	USD	29 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	-	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	-	USD	2 Qtrs
Proceeds from convertible notes	`ProceedsFromConvertibleDebt`	$435.00K	USD	29 Qtrs
Proceeds from convertible notes	`ProceedsFromConvertibleDebt`	-	USD	2 Qtrs
Proceeds from convertible notes	`ProceedsFromConvertibleDebt`	-	USD	2 Qtrs
Cash repayment of convertible notes	`RepaymentsOfConvertibleDebt`	-	USD	2 Qtrs
Cash repayment of convertible notes	`RepaymentsOfConvertibleDebt`	$15.00K	USD	29 Qtrs
Cash repayment of convertible notes	`RepaymentsOfConvertibleDebt`	-	USD	2 Qtrs
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$27.18M	USD	29 Qtrs
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$13.81M	USD	2 Qtrs
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$2.52M	USD	2 Qtrs
Net cash from financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$2.52M	USD	2 Qtrs
Net cash from financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$13.81M	USD	2 Qtrs
Net cash from financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$27.60M	USD	29 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashPeriodIncreaseDecrease`	$1.39M	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashPeriodIncreaseDecrease`	$12.17M	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashPeriodIncreaseDecrease`	$15.72M	USD	29 Qtrs
Cash, beginning of period	`Cash`	$534.05K	USD	Point-in-time
Cash, beginning of period	`Cash`	-	USD	Point-in-time
Cash, beginning of period	`Cash`	$15.72M	USD	Point-in-time
Cash, beginning of period	`Cash`	$1.93M	USD	Point-in-time
Cash, beginning of period	`Cash`	$3.55M	USD	Point-in-time
Cash, end of period	`Cash`	$534.05K	USD	Point-in-time
Cash, end of period	`Cash`	-	USD	Point-in-time
Cash, end of period	`Cash`	$15.72M	USD	Point-in-time
Cash, end of period	`Cash`	$1.93M	USD	Point-in-time
Cash, end of period	`Cash`	$3.55M	USD	Point-in-time
Interest	`InterestPaid`	-	USD	2 Qtrs
Interest	`InterestPaid`	-	USD	2 Qtrs
Interest	`InterestPaid`	$445.00	USD	29 Qtrs
Income taxes	`IncomeTaxesPaid`	-	USD	29 Qtrs
Income taxes	`IncomeTaxesPaid`	-	USD	2 Qtrs
Income taxes	`IncomeTaxesPaid`	-	USD	2 Qtrs
Common stock issued upon conversion of convertible notes	`ConversionOfStockAmountConverted1`	-	USD	2 Qtrs
Common stock issued upon conversion of convertible notes	`ConversionOfStockAmountConverted1`	$420.00K	USD	29 Qtrs
Common stock issued upon conversion of convertible notes	`ConversionOfStockAmountConverted1`	-	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.